Drugs / HD-P023
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07102719 | Sep → Oct 2025 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06889350 | Mar → Apr 2025 | — | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06339788 | May → Jun 2024 | — | Handok Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HD-P023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06889350 ↗ |
| Route | Oral | “One tablet of HD-P023 by oral” NCT06339788 ↗ |